💸 The Tape

Village Farms (NASDAQ: VFF) put out a release Tuesday welcoming the Dutch government's first formal evaluation of its regulated cannabis experiment, and the company had good reason to be pleased. The study, conducted by the Trimbos Institute, RAND Europe and Breuer & Intraval for the justice and health ministries, found the closed supply chain functioning, consumers rating value more favorably than before, product range widening, and no measurable difference in public health, livability or safety between the ten participating municipalities and ten control cities still running under the old tolerance policy.

CEO Michael DeGiglio called the program "a historic undertaking for regulated cannabis in Europe." Orville Bovenschen, who runs the company's two Dutch facilities, went further and asked for the next step: revised packaging and labeling to blunt the drift toward high-potency products, and — the line that matters — expansion of the program to more municipalities to squeeze the illicit market. Read that as a licensed grower politely telling The Hague it needs more customers.

Where the Dutch market actually stands

The Netherlands has run a legal paradox for fifty years. Selling cannabis in coffeeshops is tolerated; growing it and delivering it is not. Every gram sold at the front door arrived through a back door supplied by criminal networks while authorities looked away. The Experiment Gesloten Coffeeshopketen — the closed coffeeshop chain — is the government's attempt to close that door by licensing ten growers to supply roughly 80 coffeeshops in ten municipalities: Breda, Tilburg, Almere, Arnhem, Groningen, Heerlen, Maastricht, Nijmegen, Voorne aan Zee and Zaanstad, with Amsterdam's Oost district as a partial participant.

The experimental phase went live April 7, 2025, with a four-year term, meaning the formal window closes in spring 2029. The launch was rough: only five of ten growers could deliver on day one, hash was a disaster because legal product tasted different and cost more than the Moroccan supply coffeeshops were used to, and the government had to temporarily let shops keep buying illegal hash until enforcement kicked in on September 1, 2025. A year later, all ten growers are operational, supply has stabilized, and the Justice Inspectorate has recorded a few dozen minor infractions, four fines, and zero links to organized crime.

The licensed ten are a mix of one foreign strategic and nine domestic operators. Village Farms holds the largest and most capitalized position through its Groningen and Drachten facilities, built on the Leli Holland license it acquired in 2021. The rest are Dutch firms that emerged from the 2020 lottery — Hollandse Hoogtes, Fyta, CanAdelaar, Aardachtig and Holigram among them — most of them first-time cannabis producers who spent the last two years learning the difference between a permit and a functioning grow. That gap is why Village Farms has quietly become the reference operator: it brought decades of controlled-environment agriculture and Canadian regulatory experience into a program where most peers were figuring it out live.

What the evaluation says the release doesn't

The headline findings are positive. The details are more complicated, and they're the ones that decide what happens next.

Flower prices in the experiment cities fell from €12.06 to €10.08 a gram while rising in the control cities — a €3.35 relative decline that's statistically unambiguous. Menus exploded from 4,811 items to over 11,000. Edibles went from 34% of shops to 94%, concentrates from 17% to 70%, vapes from zero to 67%. Consumers got more choice and better value, and use didn't increase. That's the case for regulation in three sentences.

But the report also says the growers are approaching overproduction. All ten are now scaled, coffeeshops spread their purchasing across multiple suppliers to keep menus broad, and the result is falling prices, rising inventory and small volumes per SKU that make it hard for anyone to run a line efficiently. Growers told researchers financial pressure in the first phase is "high," permit delays ran longer than planned, and uncertainty about the experiment's future is already chilling investment. Their conclusion, in the government's own document: expansion to more municipalities is needed to balance the market, or some cultivators will drop out.

Hash went the other way. Prices in the experiment cities nearly doubled, hash-focused customers drifted to non-participating towns or back to the street, and the only statistically significant change in illicit purchasing the researchers found was larger illegal hash transactions in the regulated municipalities. The closed chain has solved flower and is still losing on hash — which is a large share of Dutch consumption and the product Morocco has spent decades perfecting.

That's the real story behind Village Farms' release. Ten growers built for a national market are supplying ten cities. The economics don't close at this scale, and the operator with the deepest pockets is the one asking for the map to get bigger.

Next steps

Three things now sit in front of Dutch policymakers.

First, the political decision on scope. The experiment was designed by a previous cabinet, and the current coalition has been noncommittal. The evaluation gives expansion advocates hard data — lower prices, no harm signal, no crime — and gives growers a documented supply glut to point to. Expect municipalities outside the ten, several of which have publicly asked to join, to press for entry before the 2029 sunset.

Second, product rules. Bovenschen's call for potency-conscious labeling is aimed at a real trend: with vapes and concentrates now on most menus, the regulated market is drifting toward higher-THC formats faster than the old market did. Getting ahead of that is both good policy and good positioning for the operator with the broadest product portfolio.

Third, hash. Until domestic producers can match imported hash on taste and price, the closed chain leaks. That's a cultivation and processing problem more than a regulatory one, and it's where the remaining illicit share lives.

The four-year clock runs to spring 2029, and the government will need to decide on continuation, expansion or termination well before then. Tuesday's release is Village Farms getting its argument on the record early: the experiment works, the growers need scale, and the Netherlands can either build the model European regulated market or let ten licensed producers fight over 80 shops. Deepak Anand, hired a day earlier to run global government affairs, will have his first assignment in The Hague.

📈 Dog Walkers

$CLCFF Christina Lake Has Been Asked To Dance

Three weeks after signing a non-binding letter of intent to sell itself for $15 million, Christina Lake Cannabis (CSE: CLC) (OTCQB: CLCFF) has a competing offer — and it's bigger, cleaner and faster.

Medical Saints Ltd., one of Canada's largest private licensed producers at roughly 100 tonnes of annual output, has signed a second LOI to buy substantially all of CLC's assets for $18 million in cash, on a cash-free, debt-free basis. The structure differs from the original deal: instead of acquiring the shares, Medical Saints would take the land, buildings, equipment, inventory, IP and customer lists, leaving CLC's cash and tax receivables behind with shareholders. It's a $3 million premium on headline value, plus whatever stays in the shell.

The tell that this bidder is serious is the $2 million advance, delivered to CLC's counsel on signing a definitive agreement and forfeited as liquidated damages if Medical Saints fails to fund. In a sector where LOIs routinely evaporate, a buyer willing to post non-refundable money up front is a buyer who intends to close. The exclusivity window is 40 days, subordinate to both the board's fiduciary duties and CLC's obligations under the first LOI, and the deal would require a shareholder vote.

What Medical Saints wants is obvious from CEO Lucas Leone's comment: not just the 950,000 square feet of outdoor canopy and 100 licensed acres, but the extraction and processing infrastructure CLC built for its B2B distillate business. For a 100-tonne grower, bolt-on extraction capacity is worth more than more flower.

The Special Committee formed in August will now weigh both proposals. The original Alberta buyer's exclusivity provisions permitted this, so CLC is running a de facto auction. Given the price gap, the cash structure and the deposit, the first bidder needs to improve or step aside.

For a small-cap sun-grown LP that most of the market had written off, two competing offers in a month is a remarkably good outcome. Shareholders don't need to act yet — but they should read the circular closely when it comes.

📺 Trade To Black

Something is Quietly Building in Cannabis Stocks| TTB Presented by Flowhub

• Botanical drug bill worth watching: Rep. Lauren Boebert's Advancing Botanical Drug Development Act would grant 12 years of market exclusivity to FDA-approved botanicals — and the FDA has already said cannabis-derived products qualify under that framework.

• Stigma survives rescheduling: This week's NuggMD Check-In Poll found 71% of consumers have hidden their cannabis use from someone, and 42% still hide it from loved ones today.

• Options are telling a story: Pristine Capital's Andrew O'Connell breaks down heavy volume in October 16 $6 calls and a $5 gamma wall in MSOS that could force dealer buying if price pushes through.

• Levels and catalysts: MSOS is above its December 12 anchored VWAP and outperforming the S&P; upside targets sit at $6.84, $7.25 and $11.38 with the ALJ recommendation, DEA final rule and Trulieve's Russell inclusion still on deck.